ArticleJCO precision oncology2022
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.
Pat W Whitworth et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
14 papers cite it
this papercites it